In an interview with Targeted Oncology, Jeff P. Sharman, MD, discussed the updated ELEVATE-TN data and ongoing research that is poised to define the optimal role of acalabrutinib in CLL at the 2019 ASH Annual Meeting.
Panelists discuss how belumosudil serves as a third-line therapy option for patients with chronic graft-versus-host disease (cGVHD), exploring its role in advancing treatment when earlier…
Panelists discuss how the efficacy and safety profiles of various treatment options for intermediate/poor-risk metastatic renal cell carcinoma compare, including cabozantinib monotherapy, nivolumab plus cabozantinib…
Panelists discuss how overall survival and event-free survival data presented at ESMO 2024 demonstrate promising outcomes in cancer treatment.
The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.
Yoshiaki Nakamura, MD, PhD, discusses how the use of tissue-free circulating tumor DNA (ctDNA) analysis for detecting minimal residual disease (MRD) can enhance the prediction…
In the mHSPC setting, treatment approaches are rapidly evolving, sparking ongoing debate among clinicians about the efficacy of doublet vs triplet therapy.
Noah M. Merin, MD, PhD, discusses approved therapies in acute and chronic graft-vs-host disease.
Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2-overexpressing cancers.
Panelists discuss how the first-line treatment landscape for metastatic renal cell carcinoma has evolved in recent years, considering various factors that influence decision-making for newly…
David Sallman, MD, discusses some of the innovative therapies and strategies being investigated in myelodysplastic syndromes studies.
